Mangoceuticals, Inc. (NASDAQ: MGRX) announced on October 1, 2026, that its wholly-owned subsidiary, MangoRx IP Holdings, LLC, has secured a strategic investment of $2.5 million. The funding was raised through private subscription agreements with two accredited investors, resulting in the investors acquiring a combined 25% membership interest in MangoRx IP.
Under the terms of the agreements, the investors have committed to purchase the 25% stake for $2.5 million, payable in two tranches. As of the filing date, the Company has received the initial tranche of $1.75 million. This initial payment represents a 17.5% ownership interest on a post-acquisition basis. The remaining 7.5% interest, valued at $750,000, is due no later than 60 days following the initial closing, which is set for November 28, 2026.
Crucially, the investment was made at the subsidiary level and does not involve the issuance of any shares of Mangoceuticals common stock. Consequently, the transaction does not increase the number of outstanding shares of the parent company or impact its public capitalization structure. The funds are intended to advance the commercialization of the subsidiary's patent portfolio, specifically the MGX-0024 antiviral technology.
MangoRx IP holds the patent portfolio for MGX-0024, which is protected in the U.S. under Patent No. 11,517,523. The Company states that corresponding national patents have been granted or are pending in the EU, Canada, China, India, Australia, and Japan. The investment was conducted pursuant to an exemption from registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D of the Securities Act of 1933, as the transaction did not involve a public offering.
